{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:25:16Z","timestamp":1772166316644,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Key Research and Development Program of China","award":["2022YFC2703600"],"award-info":[{"award-number":["2022YFC2703600"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An increasing number of clinical trials for new therapeutic strategies are underway or being considered for dystrophinopathy. Having detailed data on the natural progression of this condition is crucial for assessing the effectiveness of new drugs. However, there\u2019s a lack of data regarding the long-term data on the natural course and how it\u2019s managed in China. In this study, we offer a comprehensive overview of clinical and molecular findings, as well as treatment outcomes in the Chinese population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Institutional data on all patients with dystrophinopathy from August 2011 to August 2021 were retrospectively reviewed. The data included geographic distribution, age at diagnosis, molecular findings, and treatment options, such as corticosteroids, cardiac interventions, and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 2097 patients with dystrophinopathy, including 1703 cases of Duchenne muscular dystrophy (DMD), 311 cases of Becker muscular dystrophy (BMD), 46 cases of intermediate muscular dystrophy (IMD), and 37 cases categorized as \u201cpending\u201d (individuals with an undetermined phenotype), were registered in the Children\u2019s Hospital of Fudan University database for dystrophinopathy from August 2011 to August 2021. The spectrum of identified variants included exonic deletions (66.6%), exonic duplications (10.7%), nonsense variants (10.3%), splice-site variants (4.5%), small deletions (3.5%), small insertions\/duplications (1.8%), and missense variants (0.9%). Four deep intronic variants and two inversion variants were identified. Regarding treatment, glucocorticoids were administered to 54.4% of DMD patients and 39.1% of IMD patients. The median age at loss of ambulation was 2.5 years later in DMD patients who received glucocorticoid treatment. Overall, one cardiac medicine at least was prescribed to 7.4% of DMD patients, 8.3% of IMD patients, and 2.6% of BMD patients. Additionally, ventilator support was required by four DMD patients. Eligibility for exon skipping therapy was found in 55.3% of DMD patients, with 12.9%, 10%, and 9.6% of these patients being eligible for skipping exons 51, 53, and 45, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is one of the largest studies to have evaluated the natural history of dystrophinopathy in China, which is particularly conducive to the recruitment of eligible patients for clinical trials and the provision of real-world data to support drug development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-024-03217-7","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T07:02:55Z","timestamp":1724482975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comprehensive analysis of 2097 patients with dystrophinopathy based on a database from 2011 to 2021"],"prefix":"10.1186","volume":"19","author":[{"given":"Lei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuizhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-0110","authenticated-orcid":false,"given":"Xihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"issue":"15","key":"3217_CR1","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1080\/09638288.2017.1312567","volume":"40","author":"KM Conway","year":"2018","unstructured":"Conway KM, Ciafaloni E, Matthews D, Westfield C, James K, Paramsothy P, et al. Application of the International classification of functioning, disability and health system to symptoms of the Duchenne and Becker muscular dystrophies. Disabil Rehabil. 2018;40(15):1773\u201380.","journal-title":"Disabil Rehabil"},{"issue":"3","key":"3217_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367.","journal-title":"Lancet Neurol"},{"issue":"3","key":"3217_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12519-017-0036-3","volume":"13","author":"Q Ke","year":"2017","unstructured":"Ke Q, Zhao Z, Griggs R, Wiley V, Connolly A, Kwon J, et al. Newborn screening for Duchenne muscular dystrophy in China: follow-up diagnosis and subsequent treatment. World J Pediatr. 2017;13(3):197\u2013201.","journal-title":"World J Pediatr"},{"issue":"1","key":"3217_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77\u201393.","journal-title":"Lancet Neurol"},{"issue":"1","key":"3217_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13023-014-0220-7","volume":"10","author":"X Li","year":"2015","unstructured":"Li X, Zhao L, Zhou S, Hu C, Shi Y, Shi W, et al. A comprehensive database of Duchenne and Becker muscular dystrophy patients (0\u201318 years old) in East China. Orphanet J Rare Dis. 2015;10(1):5.","journal-title":"Orphanet J Rare Dis"},{"key":"3217_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cca.2022.11.024","volume":"539","author":"C Jia","year":"2023","unstructured":"Jia C, Zhao D, Li Y, Gao Y, Zhang X, Li X, et al. Newborn screening and genomic analysis of duchenne muscular dystrophy in Henan, China. Clin Chim Acta. 2023;539:90\u20136.","journal-title":"Clin Chim Acta"},{"issue":"10","key":"3217_CR7","doi-asserted-by":"publisher","first-page":"e11071","DOI":"10.1016\/j.heliyon.2022.e11071","volume":"8","author":"X Jia","year":"2022","unstructured":"Jia X, Jiang X, Huang Y. A pilot study of newborn screening for Duchenne muscular dystrophy in Guangzhou. Heliyon. 2022;8(10):e11071.","journal-title":"Heliyon"},{"issue":"17","key":"3217_CR8","first-page":"1699","volume":"76","author":"YY Syed","year":"2016","unstructured":"Syed YY, Eteplirsen. First global approval drugs. 2016;76(17):1699\u2013704.","journal-title":"First Global Approval Drugs"},{"issue":"3","key":"3217_CR9","first-page":"329","volume":"80","author":"Y Heo","year":"2020","unstructured":"Heo Y, Golodirsen. First approval drugs. 2020;80(3):329\u201333.","journal-title":"First Approval Drugs"},{"issue":"10","key":"3217_CR10","first-page":"1027","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S, Viltolarsen. First approval drugs. 2020;80(10):1027\u201331.","journal-title":"First Approval Drugs"},{"issue":"7","key":"3217_CR11","first-page":"875","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley M, Casimersen. First approval drugs. 2021;81(7):875\u20139.","journal-title":"First Approval Drugs"},{"issue":"14","key":"3217_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Delandistrogene Moxeparvovec: first approval. Drugs. 2023;83(14):1323\u20139.","journal-title":"Drugs"},{"issue":"5","key":"3217_CR13","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/jcsm.12581","volume":"11","author":"D Xu","year":"2020","unstructured":"Xu D, Zhao L, Jiang J, Li S, Sun Z, Huang X, et al. A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1. J Cachexia Sarcopenia Muscle. 2020;11(5):1306\u201320.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3217_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.actbio.2022.10.015","volume":"154","author":"S Li","year":"2022","unstructured":"Li S, Du M, Deng J, Deng G, Li J, Song Z, et al. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles. Acta Biomater. 2022;154:597\u2013607.","journal-title":"Acta Biomater"},{"issue":"2","key":"3217_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5582\/irdr.2018.01056","volume":"7","author":"J He","year":"2018","unstructured":"He J, Kang Q, Hu J, Song P, Jin C. China has officially released its first national list of rare diseases. Intractable Rare Dis Res. 2018;7(2):145\u20137.","journal-title":"Intractable Rare Dis Res"},{"issue":"9","key":"3217_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.braindev.2016.04.001","volume":"38","author":"M Goto","year":"2016","unstructured":"Goto M, Komaki H, Takeshita E, Abe Y, Ishiyama A, Sugai K, et al. Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan. Brain Develop. 2016;38(9):785\u201391.","journal-title":"Brain Develop"},{"issue":"10119","key":"3217_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451\u201361.","journal-title":"Lancet"},{"issue":"6","key":"3217_CR18","doi-asserted-by":"publisher","first-page":"e218683","DOI":"10.1371\/journal.pone.0218683","volume":"14","author":"C Brogna","year":"2019","unstructured":"Brogna C, Coratti G, Pane M, Ricotti V, Messina S, D Amico A, et al. Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS ONE. 2019;14(6):e218683.","journal-title":"PLoS ONE"},{"issue":"11","key":"3217_CR19","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.nmd.2019.09.010","volume":"29","author":"G Coratti","year":"2019","unstructured":"Coratti G, Brogna C, Norcia G, Ricotti V, Abbott L, D\u2019Amico A, et al. Longitudinal natural history in young boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2019;29(11):857\u201362.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"3217_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1750-1172-8-60","volume":"8","author":"H Nakamura","year":"2013","unstructured":"Nakamura H, Kimura E, Mori-Yoshimura M, Komaki H, Matsuda Y, Goto K, et al. Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy). Orphanet J Rare Dis. 2013;8(1):60.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3217_CR21","doi-asserted-by":"publisher","first-page":"e52512","DOI":"10.1371\/journal.pone.0052512","volume":"8","author":"ES Mazzone","year":"2013","unstructured":"Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S, et al. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS ONE. 2013;8(1):e52512.","journal-title":"PLoS ONE"},{"issue":"9","key":"3217_CR22","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1177\/0883073810371004","volume":"25","author":"RR Moxley","year":"2010","unstructured":"Moxley RR, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol. 2010;25(9):1116\u201329.","journal-title":"J Child Neurol"},{"key":"3217_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pediatrneurol.2020.08.013","volume":"113","author":"NF Miller","year":"2020","unstructured":"Miller NF, Alfano LN, Iammarino MA, Connolly AM, Moore-Clingenpeel M, Powers BR, et al. Natural history of steroid-treated young boys with Duchenne muscular dystrophy using the NSAA, 100m, and timed functional tests. Pediatr Neurol. 2020;113:15\u201320.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"3217_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.nmd.2022.02.009","volume":"32","author":"F Muntoni","year":"2022","unstructured":"Muntoni F, Signorovitch J, Sajeev G, Goemans N, Wong B, Tian C, et al. Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls. Neuromuscul Disord. 2022;32(4):271\u201383.","journal-title":"Neuromuscul Disord"},{"issue":"15","key":"3217_CR25","doi-asserted-by":"publisher","first-page":"E1009","DOI":"10.1097\/BRS.0b013e3181fea1ed","volume":"36","author":"R Roberto","year":"2011","unstructured":"Roberto R, Fritz A, Hagar Y, Boice B, Skalsky A, Hwang H, et al. The natural history of cardiac and pulmonary function decline in patients with duchenne muscular dystrophy. Spine (Phila Pa 1976). 2011;36(15):E1009\u201317.","journal-title":"Spine (Phila Pa 1976)"},{"issue":"9","key":"3217_CR26","doi-asserted-by":"publisher","first-page":"e1003222","DOI":"10.1371\/journal.pmed.1003222","volume":"17","author":"EC Smith","year":"2020","unstructured":"Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study. Plos Med. 2020;17(9):e1003222.","journal-title":"Plos Med"},{"issue":"1","key":"3217_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/JND-170272","volume":"5","author":"TB Kinane","year":"2018","unstructured":"Kinane TB, Mayer OH, Duda PW, Lowes LP, Moody SL, Mendell JR. Long-term pulmonary function in Duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history. J Neuromuscul Dis. 2018;5(1):47\u201358.","journal-title":"J Neuromuscul Dis"},{"issue":"9","key":"3217_CR28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.nmd.2021.05.005","volume":"31","author":"R Tsabari","year":"2021","unstructured":"Tsabari R, Simchovitz E, Lavi E, Eliav O, Avrahami R, Ben-Sasson S, et al. Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy. Neuromuscul Disord. 2021;31(9):803\u201313.","journal-title":"Neuromuscul Disord"},{"key":"3217_CR29","doi-asserted-by":"crossref","unstructured":"Guo J, Liu P, Chen L, Lv H, Li J, Yu W et al. National Rare Diseases Registry System (NRDRS): China\u2019s first nation-wide rare diseases demographic analyses. Orphanet J Rare Dis. 2021; 16(1).","DOI":"10.1186\/s13023-021-02130-7"},{"issue":"8","key":"3217_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.nmd.2017.02.010","volume":"27","author":"DN Wang","year":"2017","unstructured":"Wang DN, Wang ZQ, Yan L, He J, Lin MT, Chen WJ, et al. Clinical and mutational characteristics of Duchenne muscular dystrophy patients based on a comprehensive database in South China. Neuromuscul Disord. 2017;27(8):715\u201322.","journal-title":"Neuromuscul Disord"},{"key":"3217_CR31","doi-asserted-by":"crossref","unstructured":"Zhang S, Qin D, Wu L, Li M, Song L, Wei C et al. Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy. Orphanet J Rare Dis. 2021; 16(1).","DOI":"10.1186\/s13023-021-01837-x"},{"key":"3217_CR32","doi-asserted-by":"publisher","first-page":"572006","DOI":"10.3389\/fneur.2020.572006","volume":"11","author":"YR Tong","year":"2020","unstructured":"Tong YR, Geng C, Guan YZ, Zhao YH, Ren HT, Yao FX, et al. A comprehensive analysis of 2013 dystrophinopathies in China: a Report from National Rare Disease Center. Front Neurol. 2020;11:572006.","journal-title":"Front Neurol"},{"key":"3217_CR33","unstructured":"Darras BT, Urion DK, Ghosh PS, Dystrophinopathies. 2000 Sep 5 [updated 2022 Jan 20]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132024."},{"key":"3217_CR34","doi-asserted-by":"crossref","unstructured":"Okubo M, Goto K, Komaki H, Nakamura H, Mori-Yoshimura M, Hayashi YK et al. Comprehensive analysis for genetic diagnosis of dystrophinopathies in Japan. Orphanet J Rare Dis. 2017; 12(1).","DOI":"10.1186\/s13023-017-0703-4"},{"key":"3217_CR35","doi-asserted-by":"publisher","first-page":"878806","DOI":"10.3389\/fgene.2022.878806","volume":"13","author":"Y Bai","year":"2022","unstructured":"Bai Y, Liu J, Xu J, Sun Y, Li J, Gao Y, et al. Long-read sequencing revealed extragenic and intragenic duplications of exons 56\u201361 in DMD in an asymptomatic male and a DMD patient. Front Genet. 2022;13:878806.","journal-title":"Front Genet"},{"issue":"5","key":"3217_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"6","key":"3217_CR37","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/humu.20976","volume":"30","author":"S Tuffery-Giraud","year":"2009","unstructured":"Tuffery-Giraud S, Beroud C, Leturcq F, Yaou RB, Hamroun D, Michel-Calemard L, et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat. 2009;30(6):934\u201345.","journal-title":"Hum Mutat"},{"key":"3217_CR38","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.nmd.2016.06.124","volume":"26","author":"L Bello","year":"2016","unstructured":"Bello L, Morgenroth L, Gordish-Dressman H, Hoffman E, McDonald C, Cirak S. P.103 - DMD genotypes and loss of ambulation in the CINRG Duchenne natural history study. Neuromuscul Disord. 2016;26:S119.","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"3217_CR39","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","volume":"85","author":"L Bello","year":"2015","unstructured":"Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, et al. Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology. 2015;85(12):1048\u201355.","journal-title":"Neurology"},{"issue":"2","key":"3217_CR40","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/humu.20422","volume":"28","author":"N Deburgrave","year":"2007","unstructured":"Deburgrave N, Daoud F, Llense S, Barbot JC, R\u00e9can D, Peccate C, et al. Protein- and mRNA-based phenotype-genotype correlations in DMD\/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum Mutat. 2007;28(2):183\u201395.","journal-title":"Hum Mutat"},{"issue":"7","key":"3217_CR41","doi-asserted-by":"publisher","first-page":"e255011","DOI":"10.1371\/journal.pone.0255011","volume":"16","author":"U Yun","year":"2021","unstructured":"Yun U, Lee S, Choi WA, Kang S, Seo GH, Lee JH, et al. Clinical and genetic spectra in patients with dystrophinopathy in Korea: a single-center study. PLoS ONE. 2021;16(7):e255011.","journal-title":"PLoS ONE"},{"issue":"3","key":"3217_CR42","doi-asserted-by":"publisher","first-page":"e59916","DOI":"10.1371\/journal.pone.0059916","volume":"8","author":"J Juan-Mateu","year":"2013","unstructured":"Juan-Mateu J, Gonzalez-Quereda L, Rodriguez MJ, Verdura E, Lazaro K, Jou C, et al. Interplay between DMD point mutations and splicing signals in Dystrophinopathy phenotypes. PLoS ONE. 2013;8(3):e59916.","journal-title":"PLoS ONE"},{"issue":"1","key":"3217_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0960-8966(03)00169-X","volume":"14","author":"C B\u00e9roud","year":"2004","unstructured":"B\u00e9roud C, Carri\u00e9 A, Beldjord C, Deburgrave N, Llense S, Carelle N, et al. Dystrophinopathy caused by mid-intronic substitutions activating cryptic exons in the DMD gene. Neuromuscul Disord. 2004;14(1):10\u20138.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"3217_CR44","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/humu.24343","volume":"43","author":"MA Waldrop","year":"2022","unstructured":"Waldrop MA, Moore SA, Mathews KD, Darbro BW, Medne L, Finkel R, et al. Intron mutations and early transcription termination in Duchenne and Becker muscular dystrophy. Hum Mutat. 2022;43(4):511\u201328.","journal-title":"Hum Mutat"},{"issue":"1","key":"3217_CR45","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s13023-021-02089-5","volume":"16","author":"S Amselem","year":"2021","unstructured":"Amselem S, Gueguen S, Weinbach J, Clement A, Landais P. RaDiCo, the French national research program on rare disease cohorts. Orphanet J Rare Dis. 2021;16(1):454.","journal-title":"Orphanet J Rare Dis"},{"key":"3217_CR46","doi-asserted-by":"publisher","first-page":"832063","DOI":"10.3389\/fendo.2022.832063","volume":"13","author":"S Kolker","year":"2022","unstructured":"Kolker S, Gleich F, Mutze U, Opladen T. Rare disease registries are key to evidence-based Personalized Medicine: highlighting the European experience. Front Endocrinol (Lausanne). 2022;13:832063.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"3217_CR47","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s13023-021-01953-8","volume":"16","author":"A Spahr","year":"2021","unstructured":"Spahr A, Rosli Z, Legault M, Tran LT, Fournier S, Toutounchi H, et al. The LORIS MyeliNeuroGene rare disease database for natural history studies and clinical trial readiness. Orphanet J Rare Dis. 2021;16(1):328.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3217_CR48","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 duchenne muscular dystrophy mutations. Hum Mutat. 2015;36(4):395\u2013402.","journal-title":"Hum Mutat"},{"key":"3217_CR49","doi-asserted-by":"crossref","unstructured":"Kong X, Zhong X, Liu L, Cui S, Yang Y, Kong L. Genetic analysis of 1051 Chinese families with Duchenne\/Becker muscular dystrophy. Bmc Med Genet. 2019; 20(1).","DOI":"10.1186\/s12881-019-0873-0"},{"issue":"1","key":"3217_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-018-0853-z","volume":"13","author":"P Ma","year":"2018","unstructured":"Ma P, Zhang S, Zhang H, Fang S, Dong Y, Zhang Y, et al. Comprehensive genetic characteristics of dystrophinopathies in China. Orphanet J Rare Dis. 2018;13(1):109.","journal-title":"Orphanet J Rare Dis"},{"key":"3217_CR51","doi-asserted-by":"crossref","unstructured":"Tong Y, Geng C, Guan Y, Zhao Y, Ren H, Yao F et al. A comprehensive analysis of 2013 dystrophinopathies in China: a Report from National Rare Disease Center. Front Neurol. 2020; 11.","DOI":"10.3389\/fneur.2020.572006"},{"issue":"1","key":"3217_CR52","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988;2(1):90\u20135.","journal-title":"Genomics"},{"issue":"2","key":"3217_CR53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mus.20586","volume":"34","author":"A Aartsma-Rus","year":"2006","unstructured":"Aartsma-Rus A, Van Deutekom JCT, Fokkema IF, Van Ommen GB, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve. 2006;34(2):135\u201344.","journal-title":"Muscle Nerve"},{"issue":"1","key":"3217_CR54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mus.23807","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT, Han JJ, Escolar DM, Florence JM, et al. The cooperative international neuromuscular research group Duchenne natural history study\u2013a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve. 2013;48(1):32\u201354.","journal-title":"Muscle Nerve"},{"issue":"19","key":"3217_CR55","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","volume":"68","author":"WM King","year":"2007","unstructured":"King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007;68(19):1607\u201313.","journal-title":"Neurology"},{"issue":"10","key":"3217_CR56","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1177\/0883073814558120","volume":"30","author":"S Kim","year":"2015","unstructured":"Kim S, Campbell KA, Fox DJ, Matthews DJ, Valdez R. Corticosteroid treatments in males with Duchenne muscular dystrophy. J Child Neurol. 2015;30(10):1275\u201380.","journal-title":"J Child Neurol"},{"issue":"4","key":"3217_CR57","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347\u201361.","journal-title":"Lancet Neurol"},{"issue":"Supplement2","key":"3217_CR58","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1542\/peds.2018-0333I","volume":"142","author":"S Buddhe","year":"2018","unstructured":"Buddhe S, Cripe L, Friedland-Little J, Kertesz N, Eghtesady P, Finder J, et al. Cardiac Management of the patient with Duchenne muscular dystrophy. Pediatrics. 2018;142(Supplement2):S72\u201381.","journal-title":"Pediatrics"},{"key":"3217_CR59","doi-asserted-by":"crossref","unstructured":"Feingold B, Mahle WT, Auerbach S, Clemens P, Domenighetti AA, Jefferies JL et al. Management of Cardiac involvement Associated with Neuromuscular diseases: A Scientific Statement from the American Heart Association. Circulation. 2017; 136(13).","DOI":"10.1161\/CIR.0000000000000526"},{"issue":"6","key":"3217_CR60","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","volume":"56","author":"P Kieny","year":"2013","unstructured":"Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, et al. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine De Kepper centre between 1981 and 2011. Annals Phys Rehabilitation Med. 2013;56(6):443\u201354.","journal-title":"Annals Phys Rehabilitation Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03217-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03217-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03217-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T07:07:18Z","timestamp":1724483238000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03217-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3217"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03217-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3146626\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]},"assertion":[{"value":"7 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All clinical information and materials used in the present study were obtained with written informed consent from patients or their legal guardians. The study was approved by the Research Ethics Board of Children\u2019s Hospital of Fudan University([2022]300A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"311"}}